|Bid||1.550 x 2200|
|Ask||1.600 x 1000|
|Day's Range||1.550 - 1.600|
|52 Week Range||1.150 - 2.850|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.65|
Affirmed Therapeutics (AFMD) delivered earnings and revenue surprises of 5.88% and -70.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Heidelberg, Germany, August 8, 2018- Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies that harness the power of innate ...
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Affimed N.V. (NASDAQ: AFMD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30 AM Eastern Time. To listen ...
Heidelberg, Germany, August 3, 2018- Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on August ...
LONDON, UK / ACCESSWIRE / July 26, 2018 / If you want a free Stock Review on ADXS sign up now at www.wallstequities.com/registration. On Wednesday, July 25, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories.
MolMed S.p.A. (MLMD.MI), a medical biotechnology company focusing on research, development, manufacturing, and clinical validation of cell & gene therapies to treat cancer and rare diseases and AbCheck s.r.o., a technology company focusing on the discovery and optimization of high-quality human antibodies, today announced that they have entered into a three-year Master Agreement aimed at providing MolMed with selected and optimized antibodies for the development of new Chimeric Antigen Receptors (CARs), targeting both liquid and solid tumors. Under the agreement, AbCheck will use its proprietary discovery platform to select, optimize and deliver multiple human single-chain variable fragments (scFvs), specifically recognizing each MolMed target candidate.
Affimed NV (NASDAQ: AFMD ) shares were tumbling Friday after the release of updated data on its Hodgkin lymphoma treatment candidate. The metric investors are reacting to may be a decline in complete metabolic ...
Affimed N.V. (AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today presented new interim data from the Phase 1b dose escalation study evaluating AFM13, its lead NK cell engager candidate, at the European Hematology Association (EHA) 23rd Congress in Stockholm. Dr. Eva Domingo of the Instituto Catalán de Oncología L'Hospitalet, Barcelona, Spain, presented the poster, titled A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data.
Cytokinetics (NASDASQ:CYTK) looks to turn around their fortunes following last year’s unsuccessful readout of Tirasemtiv in ALS. The company’s follow on asset Reldesemtiv, is built on the same mechanism but looks to resolve the dropout issue. Further, the drug seems to be more potent than its predecessor, which may help amplify the signal we saw in respiratory function.
In today's pre-market research, WallStEquities.com evaluates Affimed N.V. (NASDAQ: AFMD), Agenus Inc. (NASDAQ: AGEN), Akcea Therapeutics Inc. (AKCA), and Akebia Therapeutics Inc. (NASDAQ: AKBA). The Company's shares are trading 8.38% above their 200-day moving average.
Heidelberg, Germany, May 30, 2018- Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, ...
If you are looking to invest in Affimed NV.’s (NASDAQ:AFMD), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...
NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Affimed N.V. (NASDAQ: AFMD ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 15, 2018 at 8:30 AM Eastern Time. To listen ...
LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on Compugen Ltd (NASDAQ: CGEN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CGEN as the Company's latest news hit the wire. On April 17, 2018, the Company announced that preclinical data presented by Bayer AG at the Annual Meeting of the American Association of Cancer Research (AACR) held April 14-18, 2018, in Chicago, Illinois, highlights the efficacy of BAY 1905254 (formerly the CGEN-15001T program) in cancer immunotherapy.
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / Affimed N.V. (NASDAQ: AFMD ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 20, 2018, at 8:30 AM Eastern Time. To listen ...